Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04696731 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
A Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Allogene Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 10
- Study locations
NCT04696731 is a Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Allogene Therapeutics. The registered enrollment target is 120 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT04696731, a Phase 1 study of Advanced/Metastatic Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Allogene Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC ALLO-316
- BIOLOGICAL ALLO-647
Study Locations (10)
California
- City of Hope - Duarte
- UCLA Medical Center - Los Angeles
- UCSF Medical Center - San Francisco
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Georgetown University Hospital - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Providence Portland Medical Center - Portland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04696731
The ClinicalTrials.gov registry entry for NCT04696731 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allogene Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced/Metastatic Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04696731 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04696731 about?
NCT04696731 is a clinical study titled "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma". This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclo...
What is the current status of trial NCT04696731?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-02-24. Estimated completion is 2025-12.
What conditions does trial NCT04696731 study?
This clinical trial studies the following conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT04696731?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ALLO-316 (GENETIC), ALLO-647 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04696731?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04696731 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.